Advanced search
Publication Cover
Immunopharmacology and Immunotoxicology Volume 35, 2013 - Issue 5
Submit an article Journal homepage
225
Views
3
CrossRef citations to date
0
Altmetric
Short Communication

Beneficial effects of Rituximab in patients with anti-MAG (myelin-associated glycoprotein) neuropathy: case reports

Nizar SouayahDepartment of Neurology and Neurosciences, University of Medicine and Dentistry of New Jersey Newark, NJUSACorrespondence[email protected]
,
Raje NoopurDivision of Hematology/Oncology, Massachusetts General Hospital Cancer Center Boston, MAUSA
&
Peter Siao Tick-ChongDepartment of Neurology, Boston University Boston, MAUSA
Pages 622-624 | Received 26 Feb 2013, Accepted 02 Jul 2013, Published online: 15 Aug 2013

References

  • Steck AJ, Murray N, Meier C, et al. Demyelinating neuropathy and monoclonal IgM antibody to myelin-associated glycoprotein. Neurology 1983;33:19–23. PubMed PMID: 6184645. Epub 1983/01/01. eng
  • Kornberg AJ, Pestronk A. Antibody-associated polyneuropathy syndromes: principles and treatment. Semin Neurol 2003;23:181–190. PubMed PMID: 12894383. Epub 2003/08/02. eng
  • Broglio L, Lauria G. Worsening after rituximab treatment in anti-mag neuropathy. Muscle Nerve 2005;32:378–379. PubMed PMID: 15986418. Epub 2005/06/30. eng
  • Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2003;1:CD002827. PubMed PMID: 12535440. Epub 2003/01/22. eng
  • Onrust SV, Lamb HM, Balfour JA. Rituximab. Drugs 1999;58:79–88; discussion 9–90. PubMed PMID: 10439931. Epub 1999/08/10. eng
  • Nobile-Orazio E. IgM paraproteinaemic neuropathies. Curr Opin Neurol 2004;17:599–605 . PubMed PMID: 15367864. Epub 2004/09/16. eng
  • Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti-MAG-associated polyneuropathy. Neurology 2006;66:742–744. PubMed PMID: 16534115. Epub 2006/03/15. eng
  • Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003;27:611–615. PubMed PMID: 12707982. Epub 2003/04/23. eng
  • Rojas-Garcia R, Gallardo E, de Andres I, et al. Chronic neuropathy with IgM anti-ganglioside antibodies: lack of long term response to rituximab. Neurology 2003;61:1814–1816. PubMed PMID: 14694058. Epub 2003/12/25. eng
  • Cornblath DR, Chaudhry V, Carter K, et al. Total neuropathy score: validation and reliability study. Neurology 1999;53:1660–1664. PubMed PMID: 10563609. Epub 1999/11/24. eng
  • Blume G, Pestronk A, Goodnough LT. Anti-MAG antibody-associated polyneuropathies: improvement following immunotherapy with monthly plasma exchange and IV cyclophosphamide. Neurology 1995;45:1577–1580. PubMed PMID: 7543988. Epub 1995/08/01. eng
  • Nobile-Orazio E, Baldini L, Barbieri S, et al. Treatment of patients with neuropathy and anti-MAG IgM M-proteins. Ann Neurol 1988;24:93–97. PubMed PMID: 2458065. Epub 1988/07/01. eng
  • Mariette X, Brouet JC, Chevret S, et al. A randomised double blind trial versus placebo does not confirm the benefit of alpha-interferon in polyneuropathy associated with monoclonal IgM. J Neurol Neurosurg Psychiatry 2000;69:279–280. PubMed PMID: 10960293. Epub 2000/08/29. eng
  • Nobile-Orazio E, Meucci N, Baldini L, et al. Long-term prognosis of neuropathy associated with anti-MAG IgM M-proteins and its relationship to immune therapies. Brain 2000;123:710–717. PubMed PMID: 10734002. Epub 2000/03/29. eng
  • Levine TD, Pestronk A. IgM antibody-related polyneuropathies: B-cell depletion chemotherapy using Rituximab. Neurology 1999;52:1701–1704. PubMed PMID: 10331706. Epub 1999/05/20. eng
  • Loyaga-Rendon RY, Taylor DO, Koval CE. Progressive multifocal leukoencephalopathy in a heart transplant recipient following rituximab therapy for antibody-mediated rejection. Am J Transplant 2013;13:1075–1079. PubMed PMID: 23489332
  • Kimby E. Tolerability and safety of rituximab (MabThera). Cancer Treat Rev 2005;31:456–473. PubMed PMID: 16054760

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.